骨保护干预对非转移性乳腺癌患者骨丢失和骨折的有效性与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入88项研究,评估双膦酸盐、地舒单抗、钙或维生素D补充对非转移性乳腺癌患者癌症治疗所致骨丢失和骨折的效果。双膦酸盐显著改善腰椎、全髋和股骨颈骨密度,并降低骨折发生率;地舒单抗效果相似但缺乏随机对照试验无法荟萃分析。双膦酸盐为 preferred 骨保护干预。
要点
- 双膦酸盐显著改善非转移性乳腺癌患者腰椎、全髋和股骨颈骨密度。
- 双膦酸盐显著降低骨折发生率(合并相对风险0.77,p<0.001)。
- 双膦酸盐最令人关注的不良事件为颌骨坏死。
核心结论
- 综合考虑有效性和安全性及证据水平,双膦酸盐是非转移性乳腺癌患者骨健康管理的首选骨保护干预。
研究设计与样本
- 系统检索MEDLINE/PubMed、Embase、Cochrane、临床试验注册库和灰色文献,纳入实验性和观察性研究,共88项研究,样本量11至4819例。
主要发现
- 双膦酸盐相比对照显著改善腰椎骨密度(合并均数差4.17,p=0.0)、全髋骨密度(1.81,p=0.034)和股骨颈骨密度(2.35,p=0.001)。
- 双膦酸盐相比对照显著降低骨折发生率(合并相对风险0.77,p<0.001)。
- 地舒单抗对骨密度和骨折发生率显示相似效果,但因缺乏随机对照试验无法进行荟萃分析。
- 双膦酸盐最令人关注的不良事件为颌骨坏死。
临床怎么用
- 对于非转移性乳腺癌患者,可优先考虑双膦酸盐以减轻癌症治疗所致骨丢失和降低骨折风险,同时监测颌骨坏死等不良事件。
局限性
- 地舒单抗因缺乏随机对照试验无法进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer treatment-induced bone loss (CTIBL) and skeletal fractures are potential consequences of anticancer therapies used in the treatment of non-metastatic breast cancer (BC). This systematic review and meta-analysis aim to synthesise the available evidence regarding the effectiveness and safety of bone protective interventions in the mitigation of CTIBL and skeletal fractures. Multiple databases including MEDLINE/PubMed, Embase and Cochrane, clinical trial registries and grey literature were systematically searched for experimental and observational studies, investigating the use of bisphosphonates, denosumab, calcium or vitamin D supplementation. Outcomes of interest were change in bone mineral density (BMD), the incidence of skeletal fractures, change in bone turnover markers, the incidence of adverse events (AEs), the presence of aromatase inhibitor musculoskeletal symptoms and quality of life. A total of 88 studies were included in our systematic review and meta-analysis, with sample sizes ranging from 11 to 4819 participants. For change in BMD outcomes able to be meta-analysed, bisphosphonates demonstrated a significant benefit compared to controls (pooled mean difference estimate; lumbar spine: 4.17, p = 0.0; total hip: 1.81, p = 0.034; femoral neck: 2.35, p = 0.001). Incidence of skeletal fractures significantly decreased with bisphosphonates compared to controls (pooled relative risk estimate; 0.77, p < 0.001). Denosumab demonstrated similar effects on BMD and skeletal fracture incidence; however, meta-analysis was not possible due to the lack of randomised controlled trials. Osteonecrosis of the jaw represents the most concerning AE with bisphosphonates. Considering the effectiveness and safety, and the level of evidence available, bisphosphonates present as the preferred bone protective intervention for the management of bone health in patients with non-metastatic BC.
引用
- Quinn MJ, Williams B, Crotti TN, et al. Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis. Osteoporos Int. 2026. PMID: 41697310. doi:10.1007/s00198-025-07786-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。